Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$135000.0.

  • Applied Therapeutics' Change in Account Payables fell 18766.23% to -$135000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 15962.75%. This contributed to the annual value of $2.7 million for FY2024, which is 19638.25% up from last year.
  • As of Q3 2025, Applied Therapeutics' Change in Account Payables stood at -$135000.0, which was down 18766.23% from -$7000.0 recorded in Q2 2025.
  • In the past 5 years, Applied Therapeutics' Change in Account Payables registered a high of $1.6 million during Q4 2024, and its lowest value of -$4.3 million during Q4 2023.
  • For the 3-year period, Applied Therapeutics' Change in Account Payables averaged around $17454.5, with its median value being $414000.0 (2024).
  • In the last 5 years, Applied Therapeutics' Change in Account Payables surged by 14769.59% in 2024 and then plummeted by 18766.23% in 2025.
  • Quarter analysis of 3 years shows Applied Therapeutics' Change in Account Payables stood at -$4.3 million in 2023, then skyrocketed by 137.44% to $1.6 million in 2024, then tumbled by 108.46% to -$135000.0 in 2025.
  • Its Change in Account Payables was -$135000.0 in Q3 2025, compared to -$7000.0 in Q2 2025 and $435000.0 in Q1 2025.